Kamada Ltd Earnings Call Signals Confident Growth Path

Kamada Ltd ((IL:KMDA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Kamada Ltd’s latest earnings call carried an upbeat tone as management highlighted double-digit revenue and profit growth, robust cash generation, and a shareholder dividend, all underpinned by strong demand for its core plasma-derived products. While executives acknowledged margin pressure, a slower plasma ramp, and product-specific headwinds, they framed these as manageable against a backdrop of solid momentum and confident 2026 guidance.

Revenue Growth

Kamada reported 2025 revenues of $180.5 million, a 12% increase from $161 million in 2024, marking another year of solid top-line expansion. Management attributed the performance to strength across key plasma-derived therapies and growing contributions from its diversified specialty portfolio.

Adjusted EBITDA Expansion

Profitability improved even faster than sales, with adjusted EBITDA rising 23% to $42 million in 2025 from $34.1 million in 2024. This expansion indicates operating leverage in the business despite modest gross margin compression and higher overhead to support commercial growth.

Net Income and EPS Improvement

Net income jumped 40% to $20.2 million in 2025, or $0.35 per diluted share, versus $14.5 million and $0.25 per share in the prior year. The increase reflects both revenue growth and disciplined cost management, giving investors evidence that earnings quality is improving.

Strong Cash Generation and Liquidity

Operating activities generated $25.5 million in cash during 2025, underscoring the cash-generative nature of Kamada’s model. The company ended the year with $75.5 million in cash and equivalents, providing ample flexibility to fund expansion initiatives and withstand potential external shocks.

Dividend Underscores Shareholder Focus

The board declared a $0.25 per share dividend, totaling about $14.4 million, in line with a policy of distributing at least half of annual net income. This payout signals management’s confidence in the company’s liquidity and earnings visibility while offering direct cash returns to shareholders.

2026 Organic Growth Guidance

Kamada’s 2026 outlook calls for revenues of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, driven entirely by organic growth. At the midpoints, this implies roughly 13% revenue growth and 23% adjusted EBITDA growth versus 2025, reinforcing the message that current momentum can continue.

KEDRAB Momentum and Long-Term Commitments

KEDRAB remained a standout performer, with 2025 sales to Kedrion of about $54 million, well above contractual minimums. Strengthening the long-term profile, Kedrion has committed to minimum orders of $90 million for 2026 and 2027, under a supply agreement that runs through 2031.

GLASSIA and VARIZIG Drive Portfolio Depth

GLASSIA contributed around $35 million in 2025 via ex-U.S. product sales and royalty streams, highlighting the value of Kamada’s AAT franchise. VARIZIG also delivered strong growth, boosted by lower vaccination rates, targeted field marketing, and a World Health Organization tender covering Latin America.

Biosimilars and Regional Distribution Expansion

Management plans to launch two additional biosimilars in Israel around mid-2026, aiming for segment revenues of $15 million to $20 million annually within four to five years. The company is also expanding distribution into the MENA region, which should broaden its geographic footprint and diversify future revenue sources.

Plasma Collection Build-Out and Future Revenue

Kamada’s U.S. plasma infrastructure is advancing, with its Houston center FDA-approved and San Antonio expected to follow in the first half of 2026. Each new center, sized at roughly 50 donor beds and 50,000 liters of annual capacity, is projected to generate $8 million to $10 million in normal-source plasma revenue at full utilization.

Ramp Timeline and Specialty Plasma Margin Upside

Current plasma center utilization stands at about 30% to 40%, and management does not expect a full ramp until the end of 2027. While this delays meaningful specialty plasma margin benefits until 2027 and beyond, the long-term plan suggests a structurally richer profit profile once the network matures.

Canadian Tender Extension Adds Visibility

In December, Kamada secured a $10 million to $14 million extension from Canadian blood services for WINRHO, HEPAGAM, CYTOGAM, and VARIZIG. The two-year award, covering Q2 2026 through Q1 2028, offers incremental revenue visibility for several key products in a stable, institutional market.

CYTOGAM Headwinds and Research Response

CYTOGAM revenues declined in 2025, as transplant centers increasingly adopted antivirals such as letermovir and maribavir to prevent CMV. Kamada is responding with a post-market research program, including the SHIELD study, seeking data to better define CYTOGAM’s role and stabilize demand over time.

Gross Margin and Q4 Profitability Pressure

Gross margin slipped to 42% in 2025 from 43% in 2024, even as gross profit climbed to $76.4 million from $70 million, reflecting an unfavorable product and market mix. This mix shift, combined with higher operating expenses, weighed on fourth-quarter profitability and resulted in lower sequential net income and EBITDA.

Cash Uses and Operating Expense Trends

Year-end cash dipped modestly to $75.5 million from $78.4 million, as Kamada deployed $9.8 million in investing activities and $18.3 million in financing, including the dividend. Operating expenses edged up to $50.2 million from $49.9 million, with higher G&A to support commercial expansion partially offset by lower R&D after halting the inhaled AAT study.

External Operating Risks

Management flagged potential export disruptions stemming from the Middle East security environment and temporary Israeli airspace closures. While they do not foresee a material long-term impact, investors were cautioned about possible short-term logistical challenges that could affect shipment timing.

Forward-Looking Outlook and Growth Drivers

Looking ahead, Kamada’s guidance rests on organic drivers such as KEDRAB’s multi-year order commitments, steady GLASSIA royalties, and ramping biosimilar and plasma businesses. Management emphasized that the 2026 revenue and EBITDA targets exclude any future acquisitions, suggesting potential upside if external growth opportunities materialize.

Kamada’s earnings call painted a picture of a specialty plasma company hitting its stride, with solid growth, rising profitability, and a shareholder-friendly capital allocation policy. Though margin mix, CYTOGAM headwinds, and a long plasma ramp introduce risks, the combination of contracted demand, strong cash generation, and visible expansion projects positions the company as a compelling name for investors tracking the plasma and rare-disease space.